Clinical Trial Update: Positron Emission Tomography Using 64Cu-SAR-bisPSMA in Participants With High-risk Prostate Cancer Prior to Radical Prostatectomy [Phase 3]

View source ↗

Summary

Clinical trial update for a Phase 3 study evaluating 64Cu-SAR-bisPSMA PET imaging in high-risk prostate cancer prior to radical prostatectomy. The study is curr…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Prostate Cancer

Drugs mentioned

• 64Cu-SAR-bisPSMA (Copper-64-labeled SAR-bisPSMA)

Snippet

Sponsor: Clarity Pharmaceuticals Ltd | Conditions: Prostate Cancer, Prostatic Neoplasms | Phase 3 | Status: RECRUITING